A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab

被引：0
|
作者：
Storniolo, AM
Burris, HA
Overmoyer, B
Silverman, P
Pegram, MD
Jones, SF
Peacock, NW
Loftiss, J
Koch, KM
Paul, E
Ho, PTC
机构：
[1] Indiana Univ, Ctr Canc, Indianapolis, IN 46204 USA
[2] Sarah Cannon Canc Ctr, Nashville, TN USA
[3] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Univ Calif Los Angeles, Ctr Hlth Sci, Los Angeles, CA 90024 USA
[5] GSK, Res Triangle Pk, NC USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S64 / S64
页数：1
相关论文
共 50 条
  • [21] An open-label, randomized, two-way crossover study to evaluate the potential inhibition of GW572016 metabolism by ketoconazole
    Smith, DA
    Bowen, C
    Herendeen, JM
    Stead, A
    Koch, KM
    Andrew, BP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 212S - 212S
  • [22] A phase I study of the dual kinase inhibitor GW572016 in combination with paclitaxel (EGF10009).
    Jones, SF
    Hainsworth, JD
    Spigel, DR
    Peacock, NW
    Willcutt, NT
    Pandite, LN
    Versola, PMJ
    Koch, KM
    Greco, F
    Burris, HA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 147S - 147S
  • [23] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Jaafar Bennouna
    Marion Deslandres
    Helene Senellart
    Cecile de Labareyre
    Rodrigo Ruiz-Soto
    Claire Wixon
    Jeff Botbyl
    A. Benjamin Suttle
    Jean-Pierre Delord
    Investigational New Drugs, 2015, 33 : 138 - 147
  • [24] A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer
    Bennouna, Jaafar
    Deslandres, Marion
    Senellart, Helene
    de Labareyre, Cecile
    Ruiz-Soto, Rodrigo
    Wixon, Claire
    Botbyl, Jeff
    Suttle, A. Benjamin
    Delord, Jean-Pierre
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (01) : 138 - 147
  • [25] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [26] A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.
    Dejonge, M.
    Savage, S.
    Verweij, J.
    Collins, T. S.
    Eskens, F.
    Whitehead, B.
    Suttle, A. B.
    Pandite, L. B.
    Ho, P. T.
    Hurwitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 142S - 142S
  • [27] Phase I and pharmacokinetics study (PK) study of the safety and tolerability of the dual EGFR1/ErbB2 tyrosine kinase (TK) inhibitor GW572016 (GW) in combination with capecitabine (C) in patients with advanced solid malignancies.
    Mita, MM
    Chu, QS
    De Bono, J
    Schwartz, G
    Curtright, J
    Hammond, LA
    Patnaik, A
    Garrison, M
    Tolcher, A
    Versola, M
    Koch, K
    Stead, A
    Smith, DA
    Pandite, L
    Rowinsky, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6100S - 6100S
  • [28] Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    Burris, HA
    Hurwitz, HI
    Dees, EC
    Dowlati, A
    Blackwell, KL
    O'Neil, B
    Marcom, PK
    Ellis, MJ
    Overmoyer, B
    Jones, SF
    Harris, JL
    Smith, DA
    Koch, KM
    Stead, A
    Mangum, S
    Spector, NL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5305 - 5313
  • [29] Pharmacokinetics and Safety of Spesolimab in Healthy Chinese Subjects: An Open-Label, Phase I Study
    Cao, Guoying
    Yang, Haijing
    Wang, Jingjing
    Ishida, Masahiro
    Thoma, Christian
    Haeufel, Thomas
    Bossert, Sebastian
    Zhang, Jing
    ADVANCES IN THERAPY, 2024, 41 (09) : 3557 - 3568
  • [30] A phase II study of lapatinib (GW572016) in recurrent/metastatic (RIM) squamous cell carcinoma of the head and neck (SCCHN).
    Abidoye, O. O.
    Cohen, E. E.
    Wong, S. J.
    Kozloff, M. F.
    Nattam, S. R.
    Stenson, K. M.
    Blair, E. A.
    Day, S.
    Dancey, J. E.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 297S - 297S
12345